Saving changes...



VCS 2020: Molecular and biological heterogeneity of canine lymphoma

VCS 2020: Molecular and biological heterogeneity of canine lymphoma

VCS 2020: Molecular and biological heterogeneity of canine lymphoma

Anne Avery
Anne Avery
on behalf of Missouri Veterinary Medical Association


$ 25.00 25.00 25.00
Normal Price: FREE $25.00


Launch date: 22 Nov 2020
Expiry Date:

Last updated: 16 Feb 2021

Reference: 196329

TIming: null

Maximum Attendees:

Places Left: 0

This course is no longer available

Exam is embedded in the course
No preview available
No Exam Available

Latest User Comments

I would like to...

Course Availability

This course is only available to trainees days after purchase. It would need to be repurchased by the trainee if not completed in the allotted time period. This course is no longer available. You will need to repurchase if you wish to take the course again.

You have null days left.


Topic: Molecular and biological heterogeneity of canine lymphoma
Lymphoproliferative disorders can be broadly classified into immature neoplasms (acute leukemia), mature B cell tumors and mature T cell tumors. Within these groups are an array of subtypes that arise from cells in different stages of development and with different functions. For example, CD4+ peripheral T cell lymphoma in dogs arises from a T cell that has not yet been activated by antigen and is recently emigrated from the thymus. By contrast, T zone lymphoma appears to be derived from a previously activated T cell and has a transcriptome most closely associated with effector T cells. In people, diffuse large B cell lymphoma can be subdivided into two clinically discrete subtypes by transcriptome profiling, and four clinically discrete subtypes by mutational analysis – each subtype is thought to arise from B cells in different phases of the germinal center/post germinal center reaction. Although most canine and human lymphomas are currently treated with broadly active cytotoxic therapies, as our understanding of the unique pathways, mutational features and antigen expression in different subtypes increases, the possibility of using more targeted therapies becomes more realistic. Both dogs and people can benefit from the use of dogs as a pre-clinical model for experimental therapies, and therefore it is important to identify where human and canine subtypes are similar and where they differ. In this session, classification, dysregulated pathways and the cell of origin of canine lymphoma/leukemia subtypes will be discussed, with an emphasis on similarities and differences with their human counterparts.


Identify the lymphoma subtypes that have the most similarity between dogs and people
Identify the specific pathways and mutations which differ between species within these shared subtypes
Identify the knowledge gaps which need to be filled as the dog becomes a model for human disease
Identify the breeds that would be the most useful resource for discovery of genetic risk factors
Anne Avery

Author Information Play Video Bio

Anne Avery
on behalf of Missouri Veterinary Medical Association

Dr. Avery is the Director of the Clinical Immunology Laboratory at Colorado State University, and a Professor in the Department of Microbiology, Immunology and Pathology. The primary focus of the Clinical Immunology Laboratory is the understanding of lymphoproliferative disorders at the clinical and molecular level, and how those disorders relate to the normal functions of cells of the immune system. She received her VMD from University of Pennsylvania, a PhD from Cornell, and completed a 3 year post doctoral fellowship at the Dana Farber Cancer Institute in Boston before moving to Colorado State University. The current focus of her laboratory is characterizing the dog as a pre-clinical model for human hematopoietic malignancy.

Current Accreditations

This course has been certified by or provided by the following Certified Organization/s:

  • Missouri Veterinary Medical Association
  • 0.25 Hours -
    Exam Attempts: 3
    Exam Pass Rate: 60
  • Veterinary Cancer Society (VSC)
  • 0.25 Units

Faculty and Disclosures

Additional Contributors

Conflicts Declared

Conflicts of Interest declaration by Author:


User Reviews (0)

Go Back


Saving changes...